Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AWH NASDAQ:MYMD NYSE:NAVB NASDAQ:VRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAWHAspira Women's Health$0.08-12.5%$0.08$0.08▼$1.58$2.44M2.011.60 million shs4.31 million shsMYMDMyMD Pharmaceuticals$0.09-7.6%$0.15$1.75▼$63.90$207K2.15134,123 shs40.31 million shsNAVBNavidea Biopharmaceuticals$0.00$0.00▼$0.13$10K1.758,503 shsN/AVRMLVermillion$0.220.0%$3.26$0.35▼$5.78$21.41M3.47440,144 shs216,092 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAWHAspira Women's Health0.00%0.00%0.00%0.00%-94.10%MYMDMyMD Pharmaceuticals-13.12%-25.02%-35.14%-48.31%-95.04%NAVBNavidea Biopharmaceuticals0.00%-50.00%-50.00%-83.33%-90.00%VRMLVermillion+22.91%+13.16%+81.82%+714.81%-84.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAWHAspira Women's HealthN/AN/AN/AN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVRMLVermillionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAWHAspira Women's Health 3.00Buy$5.506,607.32% UpsideMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/AVRMLVermillion 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAWHAspira Women's Health$9.18M0.27N/AN/A($0.23) per share-0.36MYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ANAVBNavidea Biopharmaceuticals$8.13K0.00N/AN/AN/ANaNVRMLVermillion$4.54M4.72N/AN/A$0.09 per share2.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAWHAspira Women's Health-$16.69M-$0.98N/A∞N/A-165.07%N/A-267.23%8/11/2025 (Estimated)MYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00N/AN/AN/AN/AN/AN/AVRMLVermillion-$15.24MN/AN/A∞N/A-307.31%-155.25%-103.47%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAWHAspira Women's Health$1.041,268.29%N/AN/A N/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AVRMLVermillionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAWHAspira Women's HealthN/A0.750.70MYMDMyMD PharmaceuticalsN/A0.620.62NAVBNavidea BiopharmaceuticalsN/AN/AN/AVRMLVermillion0.202.512.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAWHAspira Women's Health12.19%MYMDMyMD Pharmaceuticals9.64%NAVBNavidea Biopharmaceuticals0.01%VRMLVermillion18.09%Insider OwnershipCompanyInsider OwnershipAWHAspira Women's Health4.30%MYMDMyMD Pharmaceuticals2.12%NAVBNavidea Biopharmaceuticals43.68%VRMLVermillion4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAWHAspira Women's Health11029.76 million16.92 millionNo DataMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableVRMLVermillion4397.38 millionN/ANot OptionableVRML, AWH, MYMD, and NAVB HeadlinesRecent News About These CompaniesVermillion authorities investigate car vs building crashAugust 10, 2024 | keloland.comKVermillion, SD Hourly Weather ForecastApril 30, 2024 | wunderground.comWVermillion named Tree City USAApril 21, 2024 | siouxcityjournal.comSVermillion girls' basketball rallies to win Class A state titleMarch 13, 2024 | siouxcityjournal.comSPeoria police thwart school shooting; teen could be charged as an adultFebruary 18, 2024 | pjstar.comP2023 HW Vanguard: Dale VermillionOctober 15, 2023 | housingwire.comHGoodwill coming to VermillionSeptember 17, 2023 | siouxcityjournal.comSIn Telangana, Vermillion And Saffron Threads Were Used To Lure Women VotersSeptember 2, 2023 | outlookindia.comVermillion, SD 10-Day Weather ForecastJuly 17, 2023 | wunderground.comWA cold case without a crime: Inside the messy investigation into two missing SD teens in 1971June 21, 2023 | grandforksherald.comGCamellia VermillionJune 16, 2023 | health.usnews.comDr. Richard L. KnutsonJune 6, 2023 | health.usnews.comVermillion Elementary SchoolMay 24, 2023 | usnews.comDr. Kenneth J. VermillionMay 20, 2023 | health.usnews.comGolf: Vermillion Runner-Up At Huskies Invitational | Sports | plaintalk ... - Vermillion Plain TalkMay 13, 2023 | news.google.comNDriver killed after veering into path of dump truck on Highway 52 - Bring Me The NewsMay 13, 2023 | news.google.comNFatal crash in Vermillion Township closes portion of Highway 52 - CBS NewsMay 13, 2023 | news.google.comNVermillion, KS Weather ConditionsMay 13, 2023 | wunderground.comWVermillion Softball Falls To Tea Area 12-2 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNBaseball: Dakota Valley Blanks Vermillion 7-0 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRML, AWH, MYMD, and NAVB Company DescriptionsAspira Women's Health NASDAQ:AWHAspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.MyMD Pharmaceuticals NASDAQ:MYMD$0.09 -0.01 (-7.60%) As of 07/18/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Navidea Biopharmaceuticals NYSE:NAVBNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Vermillion NASDAQ:VRMLVermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
